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Abstract
We describe an unusual case of osteosarcoma in a Jehovah’s Witness patient who underwent chemotherapy and
major surgery without the need for blood transfusion. This 16-year-old girl presented with osteosarcoma of the
right proximal tibia requiring proximal tibia resection, followed by endoprosthesis replacement. She was
successfully treated with neoadjuvant chemotherapy and surgery with the support of haematinics, granulocyte
colony-stimulating factor, recombinant erythropoietin and intraoperative normovolaemic haemodilution. This case
illustrates the importance of maintaining effective, open communication and exploring acceptable therapeutic
alternative in the management of these patients, whilst still respecting their beliefs.
Background
Jehovah’s Witnesses are well known in the medical
world for their refusal on the acceptance of blood and
blood products [1]. Unique aspects of these beliefs can
pose health care providers with challenging medical,
legal and ethical dilemmas. Modifications of standard
transfusion practices may be necessary to respect the
beliefs of a Jehovah’s Witnesses patient and this may be
an impediment to optimal care of a patient. We describe
here a 16-year-old Jehovah’s Witness patient with osteo-
sarcoma who required a major surgery and chemother-
apy, which we believe is the first reported such case.
Case presentation
Clinical presentation
Miss S is a 16-year-old Chinese girl. She presented to a
tertiary hospital with an initial complaint of progres-
sively increasing pain and swelling of her right leg of 3
months duration. It was interfering with her right knee
movement and walking. It was not associated with any
significant trauma and started insidiously. She did not
experience any loss of appetite, loss of weight or fever
during and around the time of presentation. She had no
other known medical conditions prior to this and was
not on any medications.
Clinical and radiological findings
Examination of the patient showed a medium built girl
with a large swelling measuring 10 cm by 15 cm over
her right leg, just below the knee. She did not appear
wasted and was walking with an antalgic gait. The skin
over the swelling appeared shiny, indurated with visible
dilated veins overlying it. Her vital signs were normal
and there was no evidence of pallor. On palpation, there
was a warm hard swelling arising from the proximal
right tibia not crossing the knee joint. It was a smooth
lobular swelling, tender on deep palpation. Range of
motion for the right knee was 0° to 100° compared to 0°
to 140° on the contralateral side. There was no clinical
evidence of knee effusion. Examination of all other sys-
tems was unremarkable.
Plain radiographs (Figure 1) showed classical features
consistent with osteosarcoma of the proximal tibia. The
Magnetic Resonance Imaging showed that the tumour
was limited to the proximal tibia without involvement of
the knee joint and the neurovascular bundle was free
from the tumour (Figure 2). Computer Tomography of
the chest and bone scan revealed that the tumour was
localize to right proximal tibia without metastasis to the
lung or other bones. The clinical examination and radi-
ological findings were consistent with an initial diagnosis
of osteosarcoma of the right proximal tibia. Histopatho-
logical findings of a large-core tissue biopsy performed
showed chondromyxoid matrix and atypical chondro-
cytes containing enlarged hyperchromatic nuclei. There
were also abnormal spindle cells producing osteoid
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present. These findings were consistent with chondro-
blastic variant of osteosarcoma.
Preoperative Management
During the first encounter with the Orthopaedic Sur-
geon, the family members confirmed the Jehovah’s Wit-
ness status of the patient. Subsequently, a meeting
between the Orthopaedic Surgeon, the family members
and church representatives was held. The Hospital Liai-
son Committee for Jehovah’s Witnesses also sent repre-
sentatives to provide support to the family and medical
literature to the treating doctors for additional informa-
tion. There was acceptance towards iron and recombi-
nant erythropoietin. However, the family refused packed
red blood cells (RBC), whole blood and fresh frozen
plasma.
She was started on neoadjuvant chemotherapy which
included doxorubicin, cisplatin and high-dose metho-
trexate with leucovorin (folinic acid) rescue (Memorial
Sloan-Kettering protocol). The regime comprised of 6
cycles of chemotherapy. Surgery was performed after 3
cycles of neoadjuvant chemotherapy.
Before commencement of chemotherapy, she was
started on ferrous fumarate, folic acid, vitamin B com-
plex and subcutaneous recombinant erythropoietin
50,000 units three times a week. These measures were
expected to increase her hemoglobin levels and acceler-
ate red cell production. Immediately after her che-
motherapy, she was also given neupogen (granulocyte
colony-stimulating factor) to prevent chemotherapy-
induced neutropenia. During the course of chemother-
apy, her blood counts were stable with the range of
recorded hemoglobin of 8.7 to 13.4 g/dL, white blood
cell count of 1.9 to 14.8 × 109/L and platelet count of
77 to 268 × 109/L.
Following three cycles of chemotherapy, clinically,
there was marked reduction of the tumour mass and
patient was prepared for limb salvage surgery. A stan-
dard consent for surgery and another one for anaesthe-
sia was obtained from the parents. The parents were
clearly informed about the possible risks their child may
encounter because of refusal of blood transfusion and
this was clearly documented in the medical notes. The
patient also had a hand written note describing her reli-
gious beliefs and her refusal for blood transfusion,
which she showed to all attending doctors. This we
believe was because whilst the official medico legal con-
sent form was signed by her parents, she wanted the
treating doctors to know that the decision to refuse any
form of transfusion was without coercion from external
parties.
Three empty blood bags containing anticoagulants
routinely used for blood collection were obtained from
the blood bank to be used intraoperatively.
Surgery
A standard approach was used and the proximal tibia
was resected, followed by proximal tibia endoprosthesis
replacement. The resected tumour bone and the endo-
prosthesis used to replace the defect are shown
in Figure 3 and Figure 4. Meticulous attention to
Figure 1 Plain radiograph showing a mixed sclerosis and lytic
lesion over the right upper tibia and break in the medial
cortex.
Figure 2 Magnetic Resonance Scanning of the right tibia
showing a tumour within the right upper tibia breaching the
medial cortex to extend into the soft tissue medially.
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haemostasis was of paramount importance. A tourniquet
was used during the surgery which was released on and
off to secure haemostasis. The patient was operated in
Trendelenburg position to minimize blood loss due to
high venous pressure when the tourniquet was released.
Cell saver technique was not used because of possibility
of contamination with malignant cells.
Acute normovolaemic haemodilution
General anaesthesia with neuromuscular blockade and
controlled ventilation was used. A 20 gauge intravenous
cannula in the dorsum of the right hand was used to
induce anaesthesia. After induction, an 18 gauge cannula
was inserted in the right external jugular vein. The Tren-
delenburg position facilitated drainage of blood. Voluven
(hyroxyethyl starch 6%) was infused (in a 1:1 volume
ratio for blood extracted) through the right hand cannula
to maintain normovolaemia. 400 ml of blood was
extracted after which the flow became very sluggish. The
blood bag was connected through the second port to the
right hand cannula and reinfused without breaking the
connection. Another 18 gauge cannula was inserted into
the left internal jugular vein and a total of 600 ml of
blood was extracted while maintaining normovolaemia.
This bag was then inverted and reinfused through the
same vein at a slower rate (Figure 5). Total blood loss
during surgery was 400 ml which occurred at release of
tourniquet and this was replaced introoperatively.
Core temperature as measured with an eosophageal
probe was allowed to drop to 33.5°C, which is beneficial
to reduce basic metabolic rate, hence, the oxygen
requirement. Surgery was uneventful and took about
150 minutes to complete. Postoperatively, the limb was
bandaged and elevated to minimize blood loss.
Postoperative management
The remaining 600 ml of blood was transfused over 6
hours to replace ongoing blood loss as well as to main-
tain oxygen carrying capacity. Oxygen was administered
by face mask at 6 L/min postoperatively. The patient
was warmed to normothermia and shivering was pre-
vented. Analgesia was provided by ‘patient controlled
analgesia’ with morphine. All of the above measures
reduced oxygen demand and improved oxygen delivery.
Her postoperative hemoglobin on the next day was 9.8
g/dL. Meanwhile, the histopathological examination of
the resected tumour showed 90% tumour necrosis fol-
lowing neoadjuvant chemotherapy.
Patient was discharged after a week on full weight
bearing crutches and hematinics with a hemoglobulin
Figure 3 Resected tibia shown with endoprosthesis used to
replace the defect.
Figure 4 The endoprosthesis in-situ.
Figure 5 Autologus blood donation followed by transfusion
intraoperatively.
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level of 10 g/dL, platelet count of 120 × 109/L and white
cell count of 8 × 109/L. Her postoperative radiographs
are as shown in figure 6. Adjuvant chemotherapy using
the same agents was resumed 3 weeks after the surgery.
She completed the remaining 3 cycles of chemotherapy
uneventfully.
Discussion
Jehovah’s Witnesses number 7.3 million in the world [2].
Comparatively, this community is very rare in Malaysia
with an estimated number of 3,474 or 0.012% of
Malaysian population [2]. Nevertheless, medical practi-
tioners in Malaysia will at some point encounter these
patients and should be prepared to manage them under
various circumstances. Honoring their beliefs can create
challenging therapeutic issues especially when it’s not in
favor of the principle of beneficence and conflicts with
best medical practice.
To the medical fraternity, Jehovah’s Witnesses are best
known for their prohibition on the acceptance of blood
transfusion [1]. The blood ban forbids them from
accepting transfusion of allogeneic whole blood and its’
components which includes red blood cell (RBCs) con-
centrates, white blood cells, plasma and platelets [1,3].
The management of a case such as osteosarcoma
includes the use of high dose chemotherapy and surgery,
which entails extensive amount of dissection. Blood loss
can be significant and this eventually will require the
use of blood product supplements.
Variability exists amongst members of Jehovah’s Wit-
nesses about opinions on blood ban. Some patients may
accept fractions of blood components or recombinant
blood products such as granulocyte colony-stimulating
factor (G-CSF), recombinant human erythropoietin and
clotting fraction concentrates, whilst others will not
[1,4]. Therefore, the patient’s preference should be
clearly indicated in the medical notes.
During the surgery, normovolaemic haemodilution
was utilized, where the autologous blood remains in
continuous contact with the patient, with no interrup-
tion of the blood circuit [4,5]. This method ensures
hemodynamic stability, while maintaining a continuous
circuit between the patient and blood bag [5]. Essen-
tially, the technique of acute normovolaemic haemodilu-
tion or intraoperative haemodilution involves
withdrawing whole blood from the patient into standard
collecting blood bags before or shortly after induction of
anaesthesia. Normovolaemia is maintained by replace-
ment with crystalloid or colloid solution. The patient’s
blood can be reinfused intraoperatively and/or post-
operatively as was the case in our patient. Haemodilu-
tion is an advantage as any blood lost would contain
fewer red blood cells per unit volume [6] and the circu-
lating blood volume remains constant.
In addition to that, other strategies to conserve blood
such as ensuring effective haemostasis to minimize
blood loss and the use of tourniquet during surgery
were applied. Tourniquets are normally not used during
limb salvage surgery as this makes identifying vessels
more difficult, but such a practice can lead to more
blood loss. Therefore, for this patient a tourniquet was
used for the initial phase of superficial and deep dissec-
tion, which was subsequently released when it was time
to identify and free the neurovascular structures. Meti-
culous measures were taken to identify and secure hae-
mostasis at the end of surgery.
Chemotherapy was administered based on Memorial
Sloan-Kettering protocol and consisted of doxorubicin,
cisplatin and high-dose methotrexate. Preoperative che-
motherapy allows immediate treatment of micrometa-
static disease, aids in limb preservation and enables
assessment of chemotherapy response of the tumour.
Optimum survival is normally found in patients with
good histologic response of the preoperative chemother-
apy (more than 90% tumor necrosis) at the time of sur-
gical resection [7].
During the course of neoadjuvant chemotherapy, the
patient’s blood counts were monitored both pre and
post chemotherapy and haematinics were given from
the time of diagnosis to keep her hemoglobin counts
high. High-dose recombinant human erythropoietin was
also used. It has been shown to significantly increase the
haematocrit level with a 50% reduction in the need for
blood transfusions [8] and this is acceptable to many
Jehovah’s Witnesses. The administration of ferrous
fumarate, folic acid, recombinant erythropoietin and
G-CSF helped to maintain the hemoglobin and white
cell counts during the course of chemotherapy and
enhanced the preoperative hemoglobin levels to
13.5 g/dL. These measures are important, as a study
conducted among patients who declined blood
Figure 6 Postoperative radiographs showing the implant
within the bone with an external knee brace.
Dhanoa et al. World Journal of Surgical Oncology 2010, 8:96
http://www.wjso.com/content/8/1/96
Page 4 of 6
transfusion for religious reasons has shown that morbid-
ity and mortality rates increased dramatically when the
hemoglobin concentration decreased below 6 g/dL [9].
Kitchens [10] conducted a review of 16 reports of the
surgical outcome of a series Jehovah’s Witness patients
who were not given blood despite undergoing 1,404 sur-
gical procedures that normally would necessitate trans-
fusion. Lack of blood was the primary cause of death in
only 0.6% of patients and a contributor to death in
another 0.85% of patients.
Fortunately, the platelet count in our patient was
stable during the course of chemotherapy and there
were no episodes of bleeding. However, if the need
arises, recombinant IL-11 (oprelvekin) which is Food
and Drug Administration (FDA) approved can be admi-
nistered [11]. A systematic review examined the
appropriate ‘trigger’ for platelet transfusion after che-
motherapy or stem cell transplantation [12]. The
authors found no significant differences in mortality,
remission rates, severe bleeding events or RBC transfu-
sion requirements between a transfusion threshold of 10
to 20 × 109/L platelets.
Tenenbaum [13] analyzed the feasibility of oncology
treatment in paediatric patients with malignant disease
belonging to Jehovah’s Witnesses and concluded that
such patients can be treated similar to the other patients
with a restrictive transfusion policy and broad applica-
tion of hematopoietic supportive care measures. Also in
oncological pediatric patients receiving erythropoietin, a
significant reduction in red blood cell and platelet trans-
fusion requirements was shown [14].
While a competent adult patient has an absolute right
to refuse medical treatment, the case of adolescents
called mature minors, to decline medical treatment is
not as straightforward. In some regions, mature minors
are given a right for such consent provided that they are
deemed to have sufficient understanding and intelli-
gence to make their own decision [15]. Conversely, in
other regions, adolescents depend on parental decision-
making or that of the courts, if necessary [4,15]. Our
patient can be considered a mature minor and consent
was obtained both from the parents as well as the
patient for the decision to decline blood transfusion.
These documentation should absolve all doctors and the
hospital from any liabilities should the outcome be
adverse as a result of transfusion refusal.
Conclusion
This case is like any other case of osteosarcoma of prox-
imal tibia with one major difference. This difference lies
not in the biological or science aspect, but social
believes which has drastic impact on us, the health care
providers. This case illustrates how a major disease
which required chemotherapy and surgery was carried
out successfully in a Jehovah’s Witness patient. Building
a good rapport with the patient and maintaining effec-
tive, honest communication regarding transfusion
options without any element of coercion is the corner-
stone in the management of these patients. Rather than
discriminating Jehovah’s Witness patients because of
their beliefs, alternative modern medical care acceptable
to these patients can be used to support blood volume
and haemostatic function, during the course of treat-
ment of serious diseases.
Consent
Written informed consent was obtained from the
patient’s parents for publication of this case report and
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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